Coreline Soft Unveils "Hub-Based Operation Model" for European Lung Cancer Screening

Coreline Soft, a medical artificial intelligence (AI) company, is set to unveil its "hub-based operation model" that it is building for the European lung cancer screening market.

Coreline Soft booth installed on-site at the 2026 European Congress of Radiology (ECR 2026). Coreline Soft

원본보기 아이콘

On March 4 (local time), Coreline Soft announced that it participated in the 2026 European Congress of Radiology (ECR 2026) held in Vienna, Austria, where it introduced its AI infrastructure strategy for use in nationwide lung cancer screening systems.

In Europe, the institutionalization of lung cancer screening using low-dose CT (LDCT) is progressing rapidly. In Germany, the Federal Joint Committee (G-BA) recently proposed incorporating LDCT-based lung cancer screening into the statutory health insurance reimbursement system. France is also pursuing a roadmap to generalize lung cancer screening at the national level by 2030.

These regulatory changes are also reshaping the role of medical AI. Whereas the accuracy of image analysis algorithms was previously the main focus of competition, the core criteria are now shifting to include standardization of interpretation for large-scale screening, quality assurance (QA), automation of follow-up management, and multi-center operation capabilities. AI is evolving from being a simple diagnostic support tool to becoming an integral component of national screening infrastructure.

Coreline Soft is participating as an AI software supplier for various lung cancer screening projects, including "HANSE" in Germany, "IMPULSION" in France, "RISP" in Italy, and "4ITLR," which involves five European countries.

The company supplies both "AVIEW LCS Plus," which analyzes lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery calcification (CAC) from a single CT scan, and a central operation platform called "AVIEW HUB." AVIEW HUB centrally manages LDCT data generated from local screening institutions and automates processes such as first and second readings, interpretation discrepancy adjustment, structured report generation, and the calculation of statistics and quality management indicators.

The company explained that, through this approach, AI can go beyond merely supporting individual image interpretation and serve as an operational infrastructure that manages the entire workflow of nationwide screening programs.

At this year's congress, the company will also present research on CT image-based functional prediction. Clinical research lead Jang Ryeongwoo is scheduled to present research findings on March 5 under the theme "Development and validation of a model estimating forced vital capacity (FVC) using CT image-based anatomical data." This research demonstrates a machine learning approach to estimating lung capacity from CT image data, suggesting the potential to expand the use of imaging AI from disease diagnosis to functional assessment.

Currently, Coreline Soft's imaging AI solution "AVIEW" is being used in major tertiary medical institutions and public healthcare networks in Germany. The company noted that actual use cases are expanding from the pilot stage at individual hospitals to multi-center screening environments.

Industry observers believe that if lung cancer screening becomes institutionalized at the national level in Europe, companies with established screening operation platforms will gain a significant competitive advantage. This is because screening programs are typically operated over the long term, which leads to stable contracts and recurring revenue.

A Coreline Soft representative stated, "European lung cancer screening is moving beyond the stage of technology adoption to actual operation and standardization. Through our hub-based platform, we will support nationwide screening operations."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.